On July 9th, Gelon Hui reported that Xi'an International Medical Investment (000516.SZ) is expected to suffer a loss of 168 to 176 million yuan in the first half of the year, with a non-net loss of 132 to 142 million yuan. Although the gross profit margin of the company has gradually improved during the reporting period, the scale of its operating income hasn't yet covered the expenses. In the first half of 2024, the company's medical business will steadily develop, its disciplines will continue to strengthen, its medical service volume will increase, its revenue will continue to grow, and its losses will further narrow, demonstrating a good business development trend overall.
国际医学(000516.SZ)：预计半年度亏损1.68亿元-1.76亿元
Xi'an International Medical Investment (000516.SZ): It is expected to have a loss of 0.168 to 0.176 billion yuan in the first half of the year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.